Myeloid differentiation factor-2 activates monocytes in patients with dilated cardiomyopathy
Standard
Myeloid differentiation factor-2 activates monocytes in patients with dilated cardiomyopathy. / Feldtmann, Rico; Kümmel, Andreas; Chamling, Bishwas; Strohbach, Anne; Lehnert, Kristin; Gross, Stefan; Loerzer, Lisa; Riad, Alexander; Lindner, Diana; Westermann, Dirk; Fielitz, Jens; Dörr, Marcus; Felix, Stephan B.
in: IMMUNOLOGY, Jahrgang 167, Nr. 1, 09.2022, S. 40-53.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Myeloid differentiation factor-2 activates monocytes in patients with dilated cardiomyopathy
AU - Feldtmann, Rico
AU - Kümmel, Andreas
AU - Chamling, Bishwas
AU - Strohbach, Anne
AU - Lehnert, Kristin
AU - Gross, Stefan
AU - Loerzer, Lisa
AU - Riad, Alexander
AU - Lindner, Diana
AU - Westermann, Dirk
AU - Fielitz, Jens
AU - Dörr, Marcus
AU - Felix, Stephan B
N1 - © 2022 The Authors. Immunology published by John Wiley & Sons Ltd.
PY - 2022/9
Y1 - 2022/9
N2 - Plasma levels of myeloid differentiation factor-2 (MD-2), a co-receptor of toll-like-receptor 4 (TLR4), independently predict mortality in patients with dilated cardiomyopathy (DCM). We tested whether monocyte activation by MD-2 contributes to immune activation and inflammatory status in DCM patients. We found increased MD-2 plasma levels in 25 patients with recent-onset DCM (1250 ± 80.7 ng/ml) compared to 25 age- and gender-matched healthy controls (793.4 ± 52.0 ng/ml; p < 0.001). Monocytes isolated from DCM patients showed a higher expression (141.7 ± 12.4%; p = 0.006 vs. controls) of the MD-2 encoding gene, LY96 and an increased NF-κB-activation. Further, the TLR4-activator lipopolysaccharide (LPS) caused a higher increase in interleukin (IL)-6 in monocytes from DCM patients compared to controls (mean fluorescence intensity: 938.7 ± 151.0 vs. 466.9 ± 51.1; p = 0.005). MD-2 increased IL-6 secretion in a TLR4/NF-κB-dependent manner in monocyte-like THP-1-cells as demonstrated by TLR4-siRNA and NF-κB-inhibition. Since endothelial cells (ECs) are responsible for recruiting monocytes to the site of inflammation, ECs were treated with MD-2 leading to an activation of Akt and increased secretion of monocyte-chemoattractant-protein-1 (MCP-1). Activation of ECs by MD-2 was accompanied by an increased expression of the adhesion molecules CD54, CD106 and CD62E, resulting in an increased monocyte recruitment, which was attenuated by CD54 inhibition. In addition, in murine WT but not LY96-KO bone marrow-derived macrophages LPS increased the amount of CD54 and CD49d/CD29. MD-2 facilitates a pro-inflammatory status of monocytes and EC-mediated monocyte recruitment via TLR4/NF-κB. Elevated MD-2 plasma levels are possibly involved in monocyte-related inflammation-promoting disease progression in DCM. Our results suggest that MD-2 contributes to increasing monocytic inflammatory activity and triggers the recruitment of monocytes to ECs in DCM.
AB - Plasma levels of myeloid differentiation factor-2 (MD-2), a co-receptor of toll-like-receptor 4 (TLR4), independently predict mortality in patients with dilated cardiomyopathy (DCM). We tested whether monocyte activation by MD-2 contributes to immune activation and inflammatory status in DCM patients. We found increased MD-2 plasma levels in 25 patients with recent-onset DCM (1250 ± 80.7 ng/ml) compared to 25 age- and gender-matched healthy controls (793.4 ± 52.0 ng/ml; p < 0.001). Monocytes isolated from DCM patients showed a higher expression (141.7 ± 12.4%; p = 0.006 vs. controls) of the MD-2 encoding gene, LY96 and an increased NF-κB-activation. Further, the TLR4-activator lipopolysaccharide (LPS) caused a higher increase in interleukin (IL)-6 in monocytes from DCM patients compared to controls (mean fluorescence intensity: 938.7 ± 151.0 vs. 466.9 ± 51.1; p = 0.005). MD-2 increased IL-6 secretion in a TLR4/NF-κB-dependent manner in monocyte-like THP-1-cells as demonstrated by TLR4-siRNA and NF-κB-inhibition. Since endothelial cells (ECs) are responsible for recruiting monocytes to the site of inflammation, ECs were treated with MD-2 leading to an activation of Akt and increased secretion of monocyte-chemoattractant-protein-1 (MCP-1). Activation of ECs by MD-2 was accompanied by an increased expression of the adhesion molecules CD54, CD106 and CD62E, resulting in an increased monocyte recruitment, which was attenuated by CD54 inhibition. In addition, in murine WT but not LY96-KO bone marrow-derived macrophages LPS increased the amount of CD54 and CD49d/CD29. MD-2 facilitates a pro-inflammatory status of monocytes and EC-mediated monocyte recruitment via TLR4/NF-κB. Elevated MD-2 plasma levels are possibly involved in monocyte-related inflammation-promoting disease progression in DCM. Our results suggest that MD-2 contributes to increasing monocytic inflammatory activity and triggers the recruitment of monocytes to ECs in DCM.
KW - Animals
KW - Cardiomyopathy, Dilated/metabolism
KW - Endothelial Cells/metabolism
KW - Humans
KW - Inflammation/metabolism
KW - Lipopolysaccharides/pharmacology
KW - Lymphocyte Antigen 96/metabolism
KW - Mice
KW - Monocytes/metabolism
KW - Myeloid Differentiation Factor 88/metabolism
KW - NF-kappa B/metabolism
KW - Toll-Like Receptor 4/metabolism
U2 - 10.1111/imm.13490
DO - 10.1111/imm.13490
M3 - SCORING: Journal article
C2 - 35502635
VL - 167
SP - 40
EP - 53
JO - IMMUNOLOGY
JF - IMMUNOLOGY
SN - 0019-2805
IS - 1
ER -